korrents
Alex Telford

What Alex Telford thinks about AI and science

@alex-telford · 12 positions · On ppll ↗

Writer on biotechnology and the economics of drug development, with a background working in and around the pharmaceutical industry. He writes long, sourced essays at atelfo.github.io on why drugs are hard to discover, what regulation does to that, and where the industry is going.

Alex Telford did not write this page.

We collected these quotes from things they published elsewhere, and every quote links to where it was said. They have no account here and have not endorsed this site. Quotes are word for word; the short line under each one is our own restatement, not their wording. Their own site. Is this you? Claim it or ask us to remove it. Or tell us what is wrong here.

Filter AI and science · Newest first
Topic
All 12innovation 4AI and science 2China 2attitude change 1design 1Europe 1ideas vs execution 1neural networks 1
Sort
NewestOldest

Only Alex Telford on AI and science. See everyone on AI and science

2 dated positions, 2023 to 2024, in their own words. Our reading of what Alex Telford has said — not written or endorsed by them.

2 positions so far — this page is not yet offered to search engines.

  1. Our readingA computational discovery platform does not make a biotech fast, because the thousand other steps of drug development are still the bottleneck.

    Their wordsAnother challenge for Class II biotechs is that even if you have a nifty computational drug discovery platform, you are still often bottlenecked by the rest of the drug development process. It takes 1,000 (or more!) small steps to advance a drug through discovery, development, and past the regulators.

    ↗A new breed of biotechatelfo.github.io

  2. 9 months earlier

  3. Our readingDeep learning is not yet ready for the task that would actually add value in drug development: predicting safety and efficacy in humans.

    Their wordsit will take time for deep learning systems and training data to mature enough to be useful for the truly value-adding task of predicting safety and efficacy in humans

    ↗The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about itatelfo.github.io 8th of 9 in this piece